Loading...
In several primary prevention trials, aspirin has been shown to reduce risk for a first myocardial infarction; however, only a small proportion of subjects in these trials have been women. Now, data from the Women's Health Study provide additional information.
Nearly 40,000 generally healthy women (age, ≥45; mean age, 55) with no history of coronary or cerebrovascular disease were randomized to receive either aspirin (100 mg every other day) or placebo. During an average follow-up of 10 years, aspirin therapy, compared with placebo, was associated with the following outcomes:
a nonsignificant decrease in the combined endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death (2.4% vs. 2.6%, P=0.13)
significant decreas…